ABBV News - Candlesense

AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with seve...

What are the projected market size and revenue opportunity for upadacitinib in alopecia areata, and how will pricing, reimbursement, and off‑label use influence AbbVie's long‑term earnings outlook? What is the expected timeline for FDA submission and potential approval for the alopecia areata indication, and how might that compare to competitors' pipelines? How will the positive Phase 3 results for upadacitinib in alopecia areata affect AbbVie's short‑term stock momentum and price target?

Clinical trials

about 21 hours ago

AbbVie Completes Acquisition of Capstan Therapeutics

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platfo...

What regulatory, clinical‑trial, and integration milestones are expected for the tLNP platform, and what risks could delay or impact the anticipated upside? What are the projected revenue and margin contributions from the tLNP anti‑CD19 CAR‑T platform, and how does this compare to AbbVie’s existing pipeline and peers in the immunotherapy space? How will AbbVie’s acquisition of Capstan Therapeutics affect ABBV’s short‑term stock volatility and price target?

Mergers

3 days ago

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced co...

Are there any regulatory or tax incentives tied to the U.S. expansion that could affect the net financial benefit? What impact could the expanded API production have on AbbVie’s cost structure and gross margins? How does this investment fit within AbbVie’s broader $10 billion U.S. capital commitment strategy over the next decade?

Investment

10 days ago